GammaTile NeuroNexus Webinar: Preliminary Results from the GESTALT Trial

14 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Radiation Oncologist Lindsey Sloan, MD, PhD, reviews the preliminary results from the GESTALT trial evaluating the use of immediate radiation (GammaTile) in patients with newly diagnosed GBM.

Dr. Lindsey Sloan is an Assistant Professor, Medical Student Director and Co-lead of the Committee on Community and Belonging in the Department of Radiation Oncology at the University of Minnesota, and is a Masonic Scholar with the Masonic Cancer Center.

**

Quotes are based on the personal experience and learnings of the featured healthcare professionals.

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). GammaTile should not be used for patients with a known history of hypersensitivity to bovine-derived materials. More information on indications, contraindications, warnings, and instructions for use can be found in the GammaTile Instructions for Use. Learn more at gammatile.com.

CAUTION: The law restricts these devices to sale by or on the order of a physician.

©2025 GT Medical Technologies, Inc. GammaTile® is a registered trademark of GT Medical Technologies, Inc. All rights reserved. MKT-565-01
Categoria
Oncology
Commenta per primo questo video.

Prossimo